ACM Global Laboratory

Silver sponsor

Immunogenicity Expertise with Integrated Clinical Trial Support.

From immunogenicity strategy to clinical sample analysis, ACM Global Laboratories brings specialist bioanalytical expertise together with the capabilities of a global central laboratory, helping sponsors generate high-quality data and make confident decisions throughout drug development.

Our scientists develop, validate, and deliver fit-for-purpose Anti-Drug Antibody (ADA) and Neutralising Antibody (nAb) assays, including ACE and SPEAD approaches. We support the complete immunogenicity workflow, from assay feasibility and method development through screening, confirmation, titre, characterisation, and clinical sample analysis. Flexible strategies, including singlicate and signal-to-noise approaches, are available where scientifically and regulatorily appropriate.

Our experience spans monoclonal antibodies, therapeutic peptides, fusion proteins, ADCs, bi- and tri-specific antibodies, oligonucleotides, and biosimilars, from preclinical development through clinical trials.

What sets ACM apart is our ability to connect specialist bioanalysis with central laboratory testing, sample management, logistics, and experienced project management. With expertise across major therapeutic areas including CNS, Rare Disease, and Oncology, our teams provide scientific guidance, anticipate operational challenges, and keep studies moving from setup through completion.

All bioanalytical studies are conducted within our GLP and GCP compliant environment, combining scientific rigour with the flexibility and responsiveness needed for today’s clinical development programmes.

One partner. Integrated laboratory support. Science that keeps your programme moving.

For more information, please visit the ACM Global Laboratory website